| Home | E-Submission | Sitemap | Contact Us |  
J Korean Cancer Assoc > Volume 19(2); 1987 > Article
Journal of the Korean Cancer Association 1987;19(2): 95-101.
전이성 악성흑색종에 대한 Dimethyl Triazeno Imidazole Carboxamide ( DTC ) 의 치료효과
박근칠, 강윤구, 이재훈, 김승택, 방영주, 김노경
Dimethyl Triazeno Imidazole Carboxamide ( DTIC ) Therapy in Metastatic Malignant Melanoma
Keun Chil Park, Keun Chil Park, Jae Hoon Lee, Seung Taek Kim, Yung Jue Bang, Noe Kyeong Kim
Twenty-six patients with metastatic malignant melanoma were treated with dimethyl triazeno imidazole carboxamide (DTIC), at a dose of 250 mg/m' intravenously daily for 5 days every 3 weeks. Six of 26(23%) patients achieved partial remission with a median response duration of 15 weeks. The median survival from onset of thereapy was 28 weeks for all patients and 45 weeks for those who responded to chemotherapy. Toxicity was acceptable and easily controlled.
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Related article
A Case of the Pancreatic Pseudocyst due to Metastatic Malignant Melanoma  1997 June;29(3)
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI